Skip to content
Search

Latest Stories

Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.


Read More

Members of a women's softball team cheerfully join hands during practice on a sunny day, showcasing team spirit, cooperation, and enthusiasm for the sport.

Do trans women have a strength advantage? A look at studies on hormone therapy, muscle mass, and why it should determine eligibility in women's sports.

luza studios/Getty Images

Trans Females Are Not Biological Males - Let Them Play on Female Teams

Most Americans, Democrats as well as Republicans—many following the lead of President Trump—feel that it is not right for trans females to participate in women's sports. But the trans community, supported by those on the left wing of the Democratic Party, insists that this is part of ensuring the rights of trans people. The issue has been divisive among Democrats.

This is a complex issue. On the one hand, boys are boys, and girls are girls. That's the basic fact behind male and female sports, other than some intramural school sports that have boys and girls on the same team. Because boys are biologically stronger and faster than girls, separate leagues have been developed for both. This has nothing to do with gender identity; it is just a reflection of biological fact.

Keep ReadingShow less
An aerial view of a Flock camera

An aerial view of a Flock camera in Burbank, California. U.S. President Donald Trump expressed support for Flock cameras, saying he likes the AI-powered surveillance technology because of its use by law enforcement, despite concerns that it infringes on privacy.

(Photo by Justin Sullivan/Getty Images)

Flock Cameras Are Coming Down – but We Need More To Dismantle the Surveillance State

Chances are, you’ve seen one in your neighborhood. Flock cameras have become a major flashpoint for voters in the leadup to the midterms. The concept sounds straight out of 1984 — a network of government-owned cameras that track your movements — it’s no wonder that Americans across party lines are demanding their states and towns sever ties with the controversial company. Surveillance fears are only getting stronger as we enter the AI era.

But the problem isn’t just Flock. These cameras, Automated License Plate Readers or ALPRs to be exact, are a symptom of a larger “surveil first, ask questions later” attitude that has been adopted by local and federal government for decades. In recent years, the federal government has been dramatically expanding the nation’s surveillance infrastructure. This has taken many forms, from facial recognition technology at the airport, to law enforcement monitoring your mail, to the government watching what you’re posting on your personal social media pages. Since April, many Democrats and Republicans in Congress have united to stop what would effectively be a blank check for surveillance via FISA reauthorization, demanding surveillance reforms such as closing the “data broker loophole”, which allows the government to buy Americans’ personal data without a warrant.

Keep ReadingShow less